Status:
WITHDRAWN
S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment
Lead Sponsor:
SWOG Cancer Research Network
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibo...
Detailed Description
OBJECTIVES: * To test whether the response rate (CR, CRi, or PR) in patients with purine analog-refractory, B-cell chronic lymphocytic leukemia (CLL) after treatment with the combination of bendamust...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically and immunophenotypically confirmed diagnosis of B-cell chronic lymphocytic leukemia (CLL)
- Progressive or symptomatic disease
- Purine analog-refractory disease
- Must meet 1 of the following criteria:
- Intermediate- or high-risk modified-Rai stage
- Low-risk modified-Rai stage and progressive lymphocytosis, defined as \> 50% increase of absolute peripheral lymphocyte count over the lowest count during the past 2 months
- Received 1 or more prior therapies for CLL
- Must be registered on SWOG-9007, "Cytogenetic Studies in Leukemia Patients"
- PATIENT CHARACTERISTICS:
- Zubrod performance status 0-3
- ANC \> 1,000/mm³
- Platelet count \> 50,000/mm³
- Serum creatinine ≤ 2 times upper limit of normal (ULN) OR creatinine clearance ≥ 50 mL/min
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No systemic fungal, bacterial, viral, or other infection that is not controlled (i.e., exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
- No other prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for 5 years
- HIV positivity allowed provided the following criteria are met:
- CD4 cells \> 350/mm³
- No concurrent antiretroviral therapy
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 28 days since prior chemotherapy, any other investigational agents, or major surgery
- More than 120 days since prior allogeneic or autologous hematopoietic stem cell transplantation
- If prior allogeneic bone marrow transplantation, must meet the following criteria:
- Performed \> 120 days ago
- No acute graft-vs-host disease (GVHD) ≥ grade 2
- Receiving no immunosuppressive therapy for chronic GVHD
- No concurrent antiretroviral therapy for HIV-positive patients
- No concurrent CYP1A2 inhibitors
Exclusion
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00939328
Start Date
September 1 2009
End Date
September 1 2010
Last Update
March 6 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.